The Cambridge, MA-based biotech develops treatments that act on the gut-body network. Its pipeline consists of candidates in oncology and inflammatory diseases. Lead candidate is Phase 1-stage EDP1066 for psoriasis.
2017 Financials ($M): Operating Expenses: 27.5 (+111.5%); Net Loss: (34.1) (-127.3%); cash burn: (23.3) (-89.4%).
Update: Shares opened at $16 today, May 9.
Subscribe for full text news in your inbox